Lyell Immunopharma, Inc. Capital Expenditures
Lyell Immunopharma, Inc. (LYEL) reported Capital Expenditures of $345.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquirePropertyPlantAndEquipment · last filed 2026-08-06
- Lyell Immunopharma, Inc. payments to acquire property, plant, and equipment for the quarter ending 2026-06-30 was $256.00K, a 52.38% increase year-over-year.
- Lyell Immunopharma, Inc. payments to acquire property, plant, and equipment for the quarter ending 2026-03-31 was $89.00K, a 63.82% decline year-over-year.
- Lyell Immunopharma, Inc. payments to acquire property, plant, and equipment for the quarter ending 2025-12-31 was $304.00K, a 590.91% increase year-over-year.
- Lyell Immunopharma, Inc. payments to acquire property, plant, and equipment for the quarter ending 2025-09-30 was $62.00K, a 5.08% increase year-over-year.
- Lyell Immunopharma, Inc. payments to acquire property, plant, and equipment for fiscal 2025 was $780.00K, a 68.10% increase from fiscal 2024.
- Lyell Immunopharma, Inc. payments to acquire property, plant, and equipment for fiscal 2024 was $464.00K, a 82.73% decline from fiscal 2023.
- Lyell Immunopharma, Inc. payments to acquire property, plant, and equipment for fiscal 2023 was $2.69M, a 88.94% decline from fiscal 2022.
- Lyell Immunopharma, Inc. payments to acquire property, plant, and equipment for fiscal 2022 was $24.28M, a 62.94% decline from fiscal 2021.
| Period end | Payments to Acquire Property, Plant, and Equipment 3 month | Payments to Acquire Property, Plant, and Equipment 6 month | Payments to Acquire Property, Plant, and Equipment 9 month | Payments to Acquire Property, Plant, and Equipment 12 month |
|---|---|---|---|---|
| 2026-06-30 | $256.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $345.00K 10-Q · filed 2026-08-06 | $649.00K derived: sum of 3 quarters · filed 2026-08-06 | $711.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $89.00K 10-Q · filed 2026-05-06 | $393.00K derived: sum of 2 quarters · filed 2026-05-06 | $455.00K derived: sum of 3 quarters · filed 2026-05-06 | $623.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $304.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $366.00K derived: sum of 2 quarters · filed 2026-03-12 | $534.00K derived: sum of 3 quarters · filed 2026-08-06 | $780.00K 10-K · filed 2026-03-12 |
| 2025-09-30 | $62.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $230.00K derived: sum of 2 quarters · filed 2026-08-06 | $476.00K 10-Q · filed 2025-11-12 | $520.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $168.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $414.00K 10-Q · filed 2026-08-06 | $458.00K derived: sum of 3 quarters · filed 2026-08-06 | $517.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $246.00K 10-Q · filed 2026-05-06 | $290.00K derived: sum of 2 quarters · filed 2026-05-06 | $349.00K derived: sum of 3 quarters · filed 2026-05-06 | $680.00K derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $44.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $103.00K derived: sum of 2 quarters · filed 2026-03-12 | $434.00K derived: sum of 3 quarters · filed 2026-03-12 | $464.00K 10-K · filed 2026-03-12 |
| 2024-09-30 | $59.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $390.00K derived: sum of 2 quarters · filed 2025-11-12 | $420.00K 10-Q · filed 2025-11-12 | $445.00K derived: sum of 4 quarters · filed 2026-03-12 |
| 2024-06-30 | $331.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $361.00K 10-Q · filed 2025-08-12 | $386.00K derived: sum of 3 quarters · filed 2026-03-12 | $581.00K derived: sum of 4 quarters · filed 2026-03-12 |
| 2024-03-31 | $30.00K 10-Q · filed 2025-05-13 | $55.00K derived: sum of 2 quarters · filed 2026-03-12 | $250.00K derived: sum of 3 quarters · filed 2026-03-12 | $1.18M derived: sum of 4 quarters · filed 2026-03-12 |
| 2023-12-31 | $25.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $220.00K derived: sum of 2 quarters · filed 2026-03-12 | $1.15M derived: sum of 3 quarters · filed 2026-03-12 | $2.69M 10-K · filed 2026-03-12 |
| 2023-09-30 | $195.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $1.13M derived: sum of 2 quarters · filed 2024-11-07 | $2.66M 10-Q · filed 2024-11-07 | $7.24M derived: sum of 4 quarters · filed 2025-03-11 |
| 2023-06-30 | $933.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | $2.47M 10-Q · filed 2024-08-07 | $7.05M derived: sum of 3 quarters · filed 2025-03-11 | $9.84M derived: sum of 4 quarters · filed 2025-03-11 |
| 2023-03-31 | $1.53M 10-Q · filed 2024-05-06 | $6.12M derived: sum of 2 quarters · filed 2025-03-11 | $8.91M derived: sum of 3 quarters · filed 2025-03-11 | $16.08M derived: sum of 4 quarters · filed 2025-03-11 |
| 2022-12-31 | $4.58M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-11 | $7.37M derived: sum of 2 quarters · filed 2025-03-11 | $14.54M derived: sum of 3 quarters · filed 2025-03-11 | $24.28M 10-K · filed 2025-03-11 |
| 2022-09-30 | $2.79M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $9.96M derived: sum of 2 quarters · filed 2023-11-07 | $19.69M 10-Q · filed 2023-11-07 | $29.96M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-06-30 | $7.17M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $16.90M 10-Q · filed 2023-08-08 | $27.17M derived: sum of 3 quarters · filed 2024-02-28 | $38.77M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-03-31 | $9.73M 10-Q · filed 2023-05-04 | $20.00M derived: sum of 2 quarters · filed 2024-02-28 | $31.60M derived: sum of 3 quarters · filed 2024-02-28 | $56.05M derived: sum of 4 quarters · filed 2024-02-28 |
| 2021-12-31 | $10.27M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | $21.87M derived: sum of 2 quarters · filed 2024-02-28 | $46.31M derived: sum of 3 quarters · filed 2024-02-28 | $65.50M 10-K · filed 2024-02-28 |
| 2021-09-30 | $11.60M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $36.05M derived: sum of 2 quarters · filed 2022-11-08 | $55.24M 10-Q · filed 2022-11-08 | $80.12M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-06-30 | $24.45M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $43.64M 10-Q · filed 2022-08-04 | $68.52M derived: sum of 3 quarters · filed 2023-02-28 | $81.16M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-03-31 | $19.19M 10-Q · filed 2022-05-10 | $44.07M derived: sum of 2 quarters · filed 2023-02-28 | $56.71M derived: sum of 3 quarters · filed 2023-02-28 | |
| 2020-12-31 | $24.88M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $37.52M derived: sum of 2 quarters · filed 2023-02-28 | $51.48M 10-K · filed 2023-02-28 | |
| 2020-09-30 | $12.64M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | $26.60M 10-Q · filed 2021-11-12 | ||
| 2020-06-30 | $13.96M 10-Q · filed 2021-08-12 | |||
| 2019-12-31 | $16.05M 10-K · filed 2022-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |